The implications of vaccines for prevention of bacterial meningitis

Current Opinion in Neurology

Volumn 23, Issue 3, 2010, Pages 319-324

  Riordan, Andrew ^a  

^a ALDER HEY CHILDREN'S NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

Bacterial meningitis; Conjugate vaccines; Haemophilus influenzae type b; Neisseria meningitidis; Streptococcus pneumoniae

Indexed keywords

DIPHTHERIA PERTUSSIS POLIOMYELITIS TETANUS HAEMOPHILUS INFLUENZAE TYPE B HEPATITIS B VACCINE; HAEMOPHILUS INFLUENZAE TYPE B HEPATITIS B VACCINE; MENINGOCOCCUS OUTER MEMBRANE PROTEIN VACCINE; MENINGOCOCCUS VACCINE; MENINGOCOCCUS VESICLE VACCINE; PNEUMOCOCCUS VACCINE; UNCLASSIFIED DRUG;

ANTIBODY TITER; BACTERIAL MENINGITIS; DRUG EFFICACY; DRUG TOLERABILITY; HAEMOPHILUS INFLUENZAE TYPE B; HUMAN; IMMUNE RESPONSE; IMMUNIZATION; IMMUNOGENICITY; NEISSERIA MENINGITIDIS; NONHUMAN; REVIEW;

BACTERIAL VACCINES; DEVELOPING COUNTRIES; DRUG DESIGN; HUMANS; MENINGITIS, BACTERIAL; MENINGITIS, MENINGOCOCCAL; MENINGOCOCCAL VACCINES; NEISSERIA MENINGITIDIS; WORLD HEALTH;

EID: 77951963335     PISSN: 13507540     EISSN: None     Source Type: Journal    
DOI: 10.1097/WCO.0b013e3283381751     Document Type: Review

References (48)

1. MakwanaN, Riordan FAI. Bacterial meningitis: the impact of vaccination. CNS Drugs 2007; 21:355-366.
2. Goldblatt D, Miller E, McCloskey N, et al. Immunological response to conjugate vaccines in infants: follow up study. BMJ 1998; 316:1570-1571.
3. Trotter CL, McVernon J, Ramsay ME, et al. Optimising the use of conjugate vaccines to prevent disease caused by Haemophilus influenzae type b, Neisseria meningitidis and Streptococcus pneumoniae. Vaccine 2008; 26:4434-4445.
4. Nigrovic LE, Kuppermann N, Malley R, Bacterial Meningitis Study Group of the Pediatric Emergency Medicine Collaborative Research Committee of the American Academy of Pediatrics. Children with bacterial meningitis presenting to the emergency department during the pneumococcal conjugate vaccine era. Acad Emerg Med 2008; 15:522-528.
5. Prasad K, Karlupia N. Prevention of bacterial meningitis: an overview of Cochrane systematic reviews. Respir Med 2007; 101:2037-2043.
6. Iriso R, Ocakacon R, Acayo JA, et al. Bacterial meningitis following introduction of Hib conjugate vaccine in northern Uganda. Ann Trop Paediatr 2008; 28:211-216.
7. Russell FM, Fakakovi T, Paasi S, et al. Reduction of meningitis and impact on under-5 pneumonia after introducing the Hib vaccine in the Kingdom of Tonga. Ann Trop Paediatr 2009; 29:111-117.
8. Lee EH, Corcino M, Moore A, et al. Impact of Haemophilus influenzae type b conjugate vaccine on bacterial meningitis in the Dominican Republic. Rev Panam Salud Publica 2008; 24:161-168.
9. Verghese VP, Friberg IK, Cherian T, et al. Community effect of Haemophilus influenzae type b vaccination in India. Pediatr Infect Dis J 2009; 28:738-740.
10. Lee YC, Kelly DF, Yu LM, et al. Haemophilus influenzae type b vaccine failure in children is associated with inadequate production of high-quality antibody. Clin Infect Dis 2008; 46:186-192.
11. Hodgson A, Forgor AA, Chandramohan D, et al. A phase II, randomized study on an investigational DTPw-HBV/Hib-MenAC conjugate vaccine administered to infants in Northern Ghana. PLoS One 2008; 3:e2159.
12. Rennels M, King J Jr, Ryall R, et al. Dosage escalation, safety and immuno genicity study of four dosages of a tetravalent meningococcal polysaccharide diphtheria toxoid conjugate vaccine in infants. Pediatr Infect Dis J 2004; 23:429-435.
13. Snape MD, Perrett KP, Ford KJ, et al. Immunogenicity of a tetravalent meningococcal glycoconjugate vaccine in infants: a randomized controlled trial. JAMA 2008; 299:173-184.
14. Perrett KP, Snape MD, Ford KJ, et al. Immunogenicity and immune memory of a nonadjuvanted quadrivalent meningococcal glycoconjugate vaccine in infants. Pediatr Infect Dis J 2009; 28:186-193.
15. Jackson LA, Jacobson RM, Reisinger KS, et al. A randomized trial to determine the tolerability and immunogenicity of a quadrivalent meningococcal glycocon jugate vaccine in healthy adolescents. Pediatr Infect Dis J 2009; 28:86-91.
16. Ladhani S, Heath PT, Ramsay ME, et al. Long-term immunological follow-up of children with Haemophilus influenzae serotype b vaccine failure in the United Kingdom. Clin Infect Dis 2009; 49:372-380.
17. Patel M, Lee CK. Polysaccharide vaccines for preventing serogroup A meningococcal meningitis. Cochrane Database Syst Rev 2005:CD001093.
18. Okoko BJ, Idoko OT, Adegbola RA. Prospects and challenges with introduction of a mono-valent meningococcal conjugate vaccine in Africa. Vaccine 2009; 27:2023-2029.
19. LaForce FM, Konde K, Viviani S, Préziosi MP. The meningitis vaccine project. Vaccine 2007; 25 (Suppl 1):A97-A100.
20. Lee CH, Kuo WC, Beri S, et al. Preparation and characterization of an immunogenic meningococcal group A conjugate vaccine for use in Africa. Vaccine 2009; 27:726-732.
21. Kshirsagar N, Mur N, Thatte U, et al. Safety, immunogenicity, and antibody persistence of a new meningococcal group A conjugate vaccine in healthy Indian adults. Vaccine 2007; 25 (Suppl 1):A101-A107.
22. LaForce MF, Ravenscroft N, Djingarey M, Viviani S. Epidemic meningitis due to group A Neisseria meningitidis in the African meningitis belt: a persistent problem with an imminent solution. Vaccine 2009; 27 (Suppl 2):B13-B19.
23. Kerdpanich A, Warachit B, Kosuwon P, et al. Primary vaccination with a new heptavalent DTPw-HBV/Hib-Neisseria meningitidis serogroups A and C combined vaccine is well tolerated. Int J Infect Dis 2008; 12:88-97.
24. Gatchalian S, Palestroque E, De Vleeschauwer I, et al. The development of a new heptavalent diphtheria-tetanus-whole cell pertussis-hepatitis B-Haemophilus influenzae type b-Neisseria meningitidis serogroups A and C vaccine: a randomized dose-ranging trial of the conjugate vaccine components. Int J Infect Dis 2008; 12:278-288.
25. Reisinger KS, Baxter R, BlockSL, et al. Quadrivalent meningococcal vaccina-tion in adults: a phase III comparison of an investigational conjugate vaccine, MenACWY-CRM, with the licensed vaccine, Menactra. Clin Vaccine Immunol 2009; 16:1810-1815.
26. Black S, Klein NP, Shah J, et al. Immunogenicity and tolerability of a quad-rivalent meningococcal glycoconjugate vaccine in children 2-10 years of age. Vaccine 2010; 28:657-663.
27. Jackson LA, Baxter R, Reisinger K, et al., V59P13 Study Group. Phase III comparison of an investigational quadrivalent meningococcal conjugate vaccine with the licensed meningococcal ACWY conjugate vaccine in adolescents. Clin Infect Dis 2009; 49:e1-e10.
28. Knuf M, Kieninger-Baum D, Habermehl P, et al. A dose-range study assessing immunogenicity and safety of one dose of a new candidate meningococcal serogroups A, C,W-135, Y tetanus toxoid conjugate (MenACWY-TT) vaccine administered in the second year of life and in young children. Vaccine 2010; 28:744-753.
29. Ostergaard L, Lebacq E, Poolman J, et al. Immunogenicity, reactogenicity and persistence of meningococcal A, C, W-135 and Y-tetanus toxoid candidate conjugate (MenACWY-TT) vaccine formulations in adolescents aged 15-25 years. Vaccine 2009; 27:161-168.
30. Holst J, Martin D, Arnold R, et al. Properties and clinical performance of vaccines containing outer membrane vesicles from Neisseria meningitidis. Vaccine 2009; 27 (Suppl 2):B3-B12.
31. O'Hallahan J, McNicholas A, Galloway Y, et al. Delivering a safe and effective strain-specific vaccine to control an epidemic of group B meningococcal disease. N Z Med J 2009; 122:48-59.
32. Lennon D, Jackson C, Wong S, et al. Fast tracking the vaccine licensure process to control an epidemic of serogroup B meningococcal disease in New Zealand. Clin Infect Dis 2009; 49:597-605.
33. Wong S, Lennon D, Jackson C, et al. New Zealand epidemic strain meningococcal B outer membrane vesicle vaccine in children aged 16-24 months. Pediatr Infect Dis J 2007; 26:345-350.
34. Hosking J, Rasanathan K, Mow FC, et al. Immunogenicity, reactogenicity, and safety of a P1.7b,4 strain-specific serogroup B meningococcal vaccine given to preteens. Clin Vaccine Immunol 2007; 14:1393-1399.
35. Wong SH, Lennon DR, Jackson CM, et al. Immunogenicity and tolerability in infants of a New Zealand epidemic strain meningococcal B outer membrane vesicle vaccine. Pediatr Infect Dis J 2009; 28:385-390.
36. Kelly C, Arnold R, Galloway Y, O'Hallahan J. A prospective study of the effectiveness of the New Zealand meningococcal B vaccine. Am J Epidemiol 2007; 166:817-823.
37. Galloway Y, Stehr-Green P, McNicholas A, O'Hallahan J. Use of an observational cohort study to estimate the effectiveness of the New Zealand group B meningococcal vaccine in children aged under 5 years. Int J Epidemiol 2009; 38:413-418.
38. Gorringe AR, Taylor S, Brookes C, et al. Phase I safety and immunogenicity study of a candidate meningococcal disease vaccine based on Neisseria lactamica outer membrane vesicles. Clin Vaccine Immunol 2009; 16:1113-1120.
39. Rinaudo CD, Telford JL, Rappuoli R, Seib KL. Vaccinology in the genome era. J Clin Invest 2009; 119:2515-2525.
40. Pajon R, Yero D, Niebla O, et al. Identification of new meningococcal serogroup B surface antigens through a systematic analysis of neisserial genomes. Vaccine 2009; 28:532-541.
41. Giuliani MM, Adu-Bobie J, Comanducci M, et al. A universal vaccine for serogroup B meningococcus. Proc Natl Acad Sci USA 2006; 103:10834-10839.
42. Halperin SA, Lang ley JM, Smith B, et al. Phase 1 first-in-human studies of the reactogenicity and immunogenicity of a recombinant meningococcal NspA vaccine in healthy adults. Vaccine 2007; 25:450-457.
43. Beernink PT, Granoff DM. Bactericidal antibody responses induced by meningococcal recombinant chimeric factor H-binding protein vaccines. Infect Immun 2008; 76:2568-2575.
44. Koeberling O, Giuntini S, Seubert A, Granoff DM. Meningococcal outer membrane vesicle vaccines derived from mutant strains engineered to express factor H binding proteins from antigenic variant groups 1 and 2. Clin Vaccine Immunol 2009; 16:156-162.
45. Lucero MG, Dulalia VE, Nillos LT, et al. Pneumococcal conjugate vaccines for preventing vaccine-type invasive pneumococcal disease and X-ray defined pneumonia in children less than two years of age. Cochrane Database Syst Rev 2009:CD004977.
46. Kisakye A, Makumbi I, Nansera D, et al. Surveillance for Streptococcus pneumoniae meningitis in children aged <5 years: implications for immunization in Uganda. Clin Infect Dis 2009; 48 (Suppl 2):S153-S161.
47. Boutriau D, Poolman J, Borrow R, et al. Immunogenicity and safety of three doses of a bivalent (B:4:p1.19,15 and B:4:p1.7-2,4) meningococcal outer membrane vesicle vaccine in healthy adolescents. Clin Vaccine Immunol 2007; 14:65-73.
48. Lagos R, Munoz A, Levine MM, et al. Immunology of combining CRM(197) conjugates for Streptococcus pneumoniae, Neisseria meningitis and Haemophilus influenzae in Chilean infants. Vaccine 2009; 27:2299-2305.